The exclusive right grants Cellular Engineering Technologies the intellectual property to develop, manufacture and commercialize next generation bio-production of recombinant proteins, viral vectors for gene therapy and vaccines with a more native human post-translational modification (PTM). March 8, 2023, Coralville, Iowa – Cellular Engineering Technologies, Inc. (CET), an Iowa biotechnology company specializing in cell manufacturing … Continue reading Cellular Engineering Technologies Receives Exclusivity to Use John Paul II Medical Research Institute’s Immortalized Human Stem Cells for Commercial Bio-Production Applications